ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,780.05
      -0.21%
      US Tech 100
      19,713.54
      -0.06%
      Dow Jones
      42,454.12
      -0.14%
      Brent Oil
      79.075
      3.19%
      Bitcoin
      59,801.32
      -1.28%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Guardant Health Inc (GH) Quote

      Guardant Health Inc

      Guardant Health Inc (GH)

      Gamehost Inc
      20.61
      -0.28
      (-1.34%)
      At close: October 10 4:00PM
      Delayed by 15 minutes
      20.61
      0.00
      ( 0.00% )
      After Hours: 4:30PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      20.61
      Bid
      20.49
      Ask
      20.61
      Volume
      1,243,547
      20.36 Day's Range 20.82
      15.81 52 Week Range 37.0399
      Market Cap
      2.535B
      Previous Close
      20.89
      Open
      20.53
      Last Trade
      1
      @
      20.6
      Last Trade Time
      17:26:38
      Financial Volume
      $ 25,632,844
      VWAP
      20.6127
      Average Volume (3m)
      2,320,249
      Shares Outstanding
      123,022,076
      Dividend Yield
      -
      PE Ratio
      -5.29
      Earnings Per Share (EPS)
      -3.9
      Revenue
      563.95M
      Net Profit
      -479.45M

      About Guardant Health Inc

      Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more

      Sector
      Medical Laboratories
      Industry
      Medical Laboratories
      Website
      www.guardanthealth.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was $20.89. Over the last year, Guardant Health shares have traded in a share price range of $ 15.81 to $ 37.0399.

      Guardant Health currently has 123,022,076 shares outstanding. The market capitalization of Guardant Health is $2.57 billion. Guardant Health has a price to earnings ratio (PE ratio) of -5.29.

      Ask ADVFN Intelligence (AI)

      GH Latest News

      More News

      FeaturedZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use

      10 hours ago

      FeaturedCBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products

      10 hours ago

      Form 4 - Statement of changes in beneficial ownership of securities

      October 07 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 02 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 01 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 01 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.39-6.318181818182222.2620.54140806921.37927566CS
      4-4.27-17.162379421224.8827.1320.54214983923.93133727CS
      12-12.59-37.92168674733.237.039920.54232024927.77563495CS
      262.2412.193794229718.3737.039915.81215742126.39725347CS
      52-7.57-26.863023420928.1837.039915.81197579224.82134149CS
      156-83.12-80.1311096115103.73121.2615.81164677636.78331905CS
      260-39.29-65.59265442459.9181.0715.81138731756.51084766CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NIVFNewGenIvf Group Ltd
      $ 1.04
      (73.42%)
      		7.52M
      AGBAAGBA Group Holding Ltd
      $ 1.2194
      (18.39%)
      		369.64k
      BSFCBlue Star Foods Corporation
      $ 0.623
      (17.59%)
      		4.15M
      CETXCemtrex Inc
      $ 0.535251
      (14.13%)
      		1.93M
      LUXHLuxUrban Hotels Inc
      $ 0.057
      (12.87%)
      		1.75M
      GRTSGritstone bio Inc
      $ 0.052
      (-16.26%)
      		9.31M
      RGCRegencell Bioscience Holdings Ltd
      $ 6.00
      (-13.04%)
      		46.81k
      XCHXCHG Ltd
      $ 11.50
      (-10.37%)
      		311
      INDPIndaptus Therapeutics Inc
      $ 1.02
      (-9.73%)
      		11.32k
      CMNDClearmind Medicine Inc
      $ 1.26
      (-7.35%)
      		41.19k
      GRTSGritstone bio Inc
      $ 0.052
      (-16.26%)
      		9.31M
      NIVFNewGenIvf Group Ltd
      $ 1.04
      (73.42%)
      		7.52M
      SOFISoFi Technologies Inc
      $ 8.6203
      (-0.11%)
      		6.93M
      JTAIJet AI Inc
      $ 0.0856
      (4.77%)
      		6.29M
      MLGOMicroAlgo Inc
      $ 0.3541
      (-5.47%)
      		6.08M

      GH Discussion

      View Posts
      Monksdream Monksdream 4 weeks ago
      GH buy the dip
      👍️0
      Monksdream Monksdream 2 months ago
      GH that awful Cathie has been a recent buyer
      👍️0
      x993231 x993231 2 months ago
      I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

      X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.
      👍️0
      Monksdream Monksdream 4 months ago
      The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
      👍️0
      SubPenny0001 SubPenny0001 5 months ago
      I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
      👍️0
      jedijazz jedijazz 5 months ago
      For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
      👍️ 1 💪 1 💯 1
      jedijazz jedijazz 5 months ago
      $GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
      👍️ 1 💪 1
      jedijazz jedijazz 5 months ago
      Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

      The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

      For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
      👍️ 1 💪 1 😍 1
      jedijazz jedijazz 5 months ago
      $GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
      May 16 2024 - 8:05AM


      Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

      “One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
      👍️ 1 💯 1
      DewDiligence DewDiligence 2 years ago
      GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

      https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

      https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

      GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

      EXAS is +24%/AH, adding about $2B(!) to its market cap.

      In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
      👍️0
      jerseyboy jerseyboy 4 years ago
      I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
      👍️0
      jerseyboy jerseyboy 4 years ago
      I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
      👍️0
      jerseyboy jerseyboy 4 years ago
      So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
      👍️0
      PR_12 PR_12 4 years ago
      2-3 years I'm thinking this is @ 3-5X current share price
      👍️0

      Your Recent History

      NASDAQ
      GH
      Guardant Health
      Delayed Upgrade Clock